GLOBAL PACLITAXEL INJECTION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Size and Trends

The paclitaxel injection market is estimated to be valued at USD 6.34 Bn in 2024 and is expected to reach USD 14.44 Bn by 2031, growing at a compound annual growth rate (CAGR) of 12.5% from 2024 to 2031.

To learn more about this report, request a free sample copy

The paclitaxel injection market is expected to witness positive growth over the forecast period. Increasing incidence and prevalence of cancers globally is further expected to boost the demand for more effective treatment options like paclitaxel injection. Many pipeline drugs and novel drug delivery technologies for paclitaxel are under development which can improve efficacy and reduce toxicities associated with the treatment. This is also expected positively to impact the paclitaxel injection market growth during the forecast period.

High prevalence of cancer

Cancer has become one of the leading causes of mortality worldwide with over 20 million new cases reported annually. The high prevalence rate of cancer definitely increases the demand for effective therapeutics in the market. According to an article published by Centers for Disease Control and Prevention, a national public health agency of the U.S., In the U.S., 1,603,844 new cancer cases were reported in 2020, with 602,347 people died of cancer. For every 100,000 people, 403 new cancer cases were reported, with 144 people died from cancer.

Paclitaxel injection has proven to be an important drug in cancer treatment because of its unique mechanism of action that stabilizes microtubules and inhibits their disassembly, thereby blocking cell division and slow down tumor cell growth. As the incidence of cancer diagnoses continues to rise each year due to aging population and changing lifestyle habits, the demand for paclitaxel injection from hospitals and cancer treatment centers will also see a simultaneous rise. 

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

Adoption of inorganic growth strategies by key market players

The adoption of inorganic growth strategies, such as acquisitions, partnerships, and collaborations, by key market players is one of the major factors propelling the growth of the paclitaxel injection market. Players in the market are focusing on expanding their product portfolios and strengthening their market presence through inorganic growth strategies. For instance, in August 2022, CHEPLAPHARM, a pharmaceutical company, announced the acquisition of Bristol Myers Squibb, a pharmaceutical company, product portfolio comprising three chemotherapeutical medicinal products, including the well-known names Taxol, Hydrea/Litalir/Droxia, and Paraplatin.  For the past 50 years, these medications have been sold internationally, with a focus on Asian markets, and they are well-known among both prescribers and patients. Paclitaxel injection, also known as Taxol, is one of the most often used anticancer medications. It is used to treat ovarian cancer, breast carcinoma, non-small cell lung carcinoma, Kaposi's sarcoma, and gastric cancer. It is commonly used as a first-line treatment option, particularly in breast cancer. 

To learn more about this report, request a free sample copy

Market Challenges – Development of alternative treatment options:

The paclitaxel injection market faces several challenges. The expiry of patents for many branded formulations has led to increased competition from generic manufacturers, pressuring prices downwards. Additionally, the development of newer drug therapies to treat cancers means paclitaxel injection faces competition from substitute products. Stringent regulatory norms have raised clinical trial costs, affecting the entry of new players. Potential side effects from use of paclitaxel injection like myelosuppression also pose concerns.

Market Opportunities – Rise in research and development activities:

The rise in research and development activities presents a great opportunity for growth in the paclitaxel injection market. Pharmaceutical companies and research institutes have been investing heavily in clinical trials and experiments to develop more effective formulations of paclitaxel that can help achieve higher success rates in cancer treatment. There is a strong push for discovering methods to deliver paclitaxel in a targeted manner directly to the tumor sites. Many ongoing studies are evaluating innovative drug delivery systems like nanoparticle-mediated injections, implantable drug reservoirs, etc. that can transport paclitaxel specifically to cancer cells while avoiding exposure to healthy tissues. This targeted approach can help maximize the drug's therapeutic benefits while minimizing unwanted side effects faced by patients. For example, recent pre-clinical research conducted at Johns Hopkins University tested paclitaxel-loaded gelatin nanoparticles that showed potential for controlled release of the drug directly at breast cancer sites over an extended period of 4-6 weeks.

To learn more about this report, request a free sample copy

The cancer type segment includes breast cancer, gastric cancer, pancreatic cancer, non-small cell lung cancer, ovarian cancer, kaposi sarcoma, and others. Breast cancer is anticipated to hold 26.8% of the total market share in 2024. The high prevalence rate can be attributed to multiple factors such as increasing awareness leading to early detection, lifestyle changes, and growing elderly female population who are at a higher risk of developing breast cancer. Paclitaxel is one of the key chemotherapy drugs used for the treatment of breast cancer. It works by inhibiting tumor cell growth and multiplication. It is commonly used along with other therapies such as surgery, radiation, hormone therapy, or targeted drug therapy. The development of new drug formulations and treatment regimens incorporating paclitaxel injection have improved treatment outcomes for breast cancer patients.

Various governments and non-profit organizations are working towards breast cancer screening programs and awareness campaigns. Initiatives focused on counseling, annual mammograms, and genetic testing aim to detect breast cancer at an early stage when cure rates are high. Charitable organizations provide financial assistance for the treatment to underprivileged patients. This has further driven the demand for paclitaxel injection from the breast cancer segment.

Insights, By Distribution Channel: Direct access to patients and insurance coverage promotes hospital pharmacies growth

The distribution channel segment includes online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies segment is expected to account for 45.6% of the market share in 2024. Hospital pharmacies form the main distribution channel for paclitaxel injection considering it is generally administered by intravenous route under medical supervision. Being present within healthcare facilities, hospital pharmacies have direct access to cancer patients undergoing chemotherapy. They also benefit from established contracts and tie-ups with insurance providers for drug reimbursements.

Most treatments involving paclitaxel injection require prolonged hospital stay of patients. This provides opportunities for hospital pharmacies to regularly supply the drug and other supportive medications throughout the course. The changing treatment patterns incorporating paclitaxel with other therapies like surgery also contribute to its higher sales through hospitals. Various hospitals have established specialized cancer care centers with qualified personnel for safe handling and administering paclitaxel and other chemotherapy medications. This makes hospital pharmacies the most optimized channel for the drug.

Regional Insights

To learn more about this report, request a free sample copy

North America has dominated the global paclitaxel injection market for many years owing to the strong presence of major industry players and a well-established healthcare system in the region. North America is expected to account for 42.5% of the market share in 2024. The U.S. accounts for the lion's share of the North America paclitaxel injection market and is home to leading pharmaceutical companies with vast resources for extensive R&D activities and new drug development. These companies introduced several innovative drug delivery mechanisms and therapeutic applications of paclitaxel which established the region's supremacy in this market. Moreover, the easy availability of paclitaxel injection formulations and higher healthcare spending has continued to drive the North American market.

Asia Pacific has emerged as the fastest growing regional market for paclitaxel injections in recent times. China plays a pivotal role in shaping the fortunes of the Asia Pacific paclitaxel injection market. The large patient population and increasing incidence of cancer coupled with the growing healthcare infrastructure in the country has boosted the demand for cost-effective cancer therapies including paclitaxel injection. Additionally, several domestic pharmaceutical producers catering to the local needs have entered into the production of generic paclitaxel formulations. Their aggressive pricing strategies to capture market share has augmented the overall market growth rate. India too has contributed significantly owing to its position as the global hub for generic medicines. The ready availability of qualified pharmaceutical talent and comparative low manufacturing costs gives Indian companies a competitive edge in the global market.

Europe holds the second spot in terms of regional market share attributable mainly to large economies like Germany, the U.K., and France. However, pricing pressures due to stringent drug price control policies and payor rejections are limiting revenue potential in this region. Despite such setbacks, initiatives by research institutes towards development of advanced drug delivery systems and combination therapies with paclitaxel offer new prospects for growth. Similarly, improving access to innovative oncology treatments across Central and Eastern European countries is bolstering the regional market demand. With these factors, Europe remains an important and profitable regional market for paclitaxel injections worldwide.

Market Report Scope

Key Developments

• In November 2023, GSK, a biopharmaceutical company, announced that Health Canada, the department of the Government of Canada responsible for national health policy approved a new indication for Jemperli (dostarlimab injection) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy, based on Part 1 of the pivotal RUBY study.
• In May 2023, American Regent, Inc., a pharmaceutical company, announced the launch of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), an alternative to Abraxane. Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) is a microtubule inhibitor used to treat metastatic breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma.
• In October 2022, Alembic Pharmaceuticals, a pharmaceutical company, received final approval from the U.S. health agency for its generic version of paclitaxel injection, which is used to treat some types of cancer. The U.S. Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for Paclitaxel injection in strengths of 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) multiple-dose vials.
• In April 2022, Apotex Inc., a pharmaceutical corporation, announced the release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic form of Abraxane in the U.S. Paclitaxel protein-bound particles for injectable suspension are suggested to treat metastatic breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma.

*Definition:

The paclitaxel injection market involves the production and sales of the cancer drug paclitaxel that is administered to patients through injection. Paclitaxel works by stopping the growth of cancer cells and limiting the spread of tumors. The global paclitaxel injection market has seen significant growth in recent years attributed to the growing prevalence of cancer.

Market Segmentation

•  Cancer Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Breast Cancer
  • Gastric Cancer
  • Pancreatic Cancer
  • Non-small Cell Lung Cancer
  • Ovarian Cancer
  • Kaposi sarcoma
  • Others
•  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Bristol-Myers Squibb Company
  • U & V Cancure Private Limited
  • Pfizer Inc.
  • Luye Pharma Group
  • Fresenius Kabi AG 
  • Accord Healthcare 
  • Viatris Inc. 
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd. 
  • Sandoz Group AG
  • Salvavidas
  • Sun Pharmaceutical Industries Ltd.  
  • Cipla Inc. 
  • Alvogen 
  • Apotex Inc.
  • Bharat Parenterals Limited